Literature DB >> 11259616

2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.

A Azuma1, P Huang, A Matsuda, W Plunkett.   

Abstract

The mechanism of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC) action was investigated in human lymphoblastoid CEM cells and myeloblastic leukemia ML-1 cells. CNDAC was metabolized to its 5'-triphosphate and incorporated into DNA, which was associated with inhibition of DNA synthesis. After incubation of cells with [(3)H]CNDAC, metabolites were detected in 3'-->5' phosphodiester linkage and at the 3' terminus of cellular DNA. Specific enzymatic hydrolysis of DNA demonstrated that the parent nucleoside and its 2'-epimer 2'-C-cyano-2'-deoxy-2-ribo-pentofuranosylcytosine accounted for approximately 65% of the total analogs incorporated into DNA and essentially all of the drug in the 3'-->5' phosphodiester linkage. In contrast, all detectable radioactivity at 3' termini was associated with 2'-C-cyano-2',3'-didehydro-2',3'-dideoxycytidine. This de facto DNA chain-terminating nucleotide arises from an electronic characteristic and cleavage of the 3'-phosphodiester bond subsequent to the addition of a nucleotide to the incorporated CNDAC moiety by beta-elimination, a process that generates a single strand break in DNA. Investigation of the biological consequences of these actions indicated that, after incubation with cytostatic concentrations of CNDAC, cell cycle progression was delayed during S phase, but that cells arrested predominantly in the G(2) phase. This differed from the S phase-arresting actions of ara-C and gemcitabine, other deoxycytidine analogs that inhibit DNA replication but do not cause strand breaks. Thus, once incorporated into DNA, the CNDAC molecule appears to act by a dual mechanism that 1) delays the progress of further DNA replication, but 2) upon addition of a deoxynucleotide results in the conversion of the incorporated analog to a de facto DNA chain terminator at the 3' terminus of a single strand break. It is likely that DNA strand breaks trigger cell cycle arrest in G(2).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259616     DOI: 10.1124/mol.59.4.725

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  30 in total

1.  Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.

Authors:  Xiaojun Liu; Yaqing Wang; Sherri Benaissa; Akira Matsuda; Hagop Kantarjian; Zeev Estrov; William Plunkett
Journal:  Blood       Date:  2010-05-17       Impact factor: 22.113

2.  Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.

Authors:  Deepa Sampath; Jorge Cortes; Zeev Estrov; Min Du; Zheng Shi; Michael Andreeff; Varsha Gandhi; William Plunkett
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

3.  TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.

Authors:  Muthana Al Abo; Hiroyuki Sasanuma; Xiaojun Liu; Vinodh N Rajapakse; Shar-Yin Huang; Evgeny Kiselev; Shunichi Takeda; William Plunkett; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2017-08-11       Impact factor: 6.261

4.  Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC.

Authors:  Xiaojun Liu; Yingjun Jiang; Billie Nowak; Sarah Hargis; William Plunkett
Journal:  Mol Cancer Ther       Date:  2016-07-29       Impact factor: 6.261

5.  Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

Authors:  Xiaojun Liu; Yingjun Jiang; Billie Nowak; Bethany Qiang; Nancy Cheng; Yuling Chen; William Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  2017-11-30       Impact factor: 3.333

6.  A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.

Authors:  Thierry Delaunoit; Patrick A Burch; Joel M Reid; John K Camoriano; Tomowo Kobayash; Theodore A Braich; Judith S Kaur; Joseph Rubin; Charles Erlichman
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

7.  Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360).

Authors:  Godefridus J Peters; Kees Smid; Leonardo Vecchi; Ietje Kathmann; Dzjemma Sarkisjan; Richard J Honeywell; Nienke Losekoot; Osnat Ohne; Aric Orbach; Eran Blaugrund; Lak Shin Jeong; Young Bok Lee; Chang-Ho Ahn; Deog Joong Kim
Journal:  Invest New Drugs       Date:  2013-09-19       Impact factor: 3.850

8.  Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.

Authors:  Hagop Kantarjian; Stefan Faderl; Guillermo Garcia-Manero; Selina Luger; Parameswaran Venugopal; Lori Maness; Meir Wetzler; Steven Coutre; Wendy Stock; David Claxton; Stuart L Goldberg; Martha Arellano; Stephen A Strickland; Karen Seiter; Gary Schiller; Elias Jabbour; Judy Chiao; William Plunkett
Journal:  Lancet Oncol       Date:  2012-10-15       Impact factor: 41.316

9.  Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.

Authors:  Hagop Kantarjian; Guillermo Garcia-Manero; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Robert Westwood; Simon R Green; Judy H Chiao; Patricia A Boone; Jorge Cortes; William Plunkett
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

10.  Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines.

Authors:  Zhongde Wang; Joy Martinez; Wendi Zhou; Corinna La Rosa; Tumul Srivastava; Anindya Dasgupta; Ravindra Rawal; Zhongqui Li; William J Britt; Don Diamond
Journal:  Vaccine       Date:  2009-12-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.